Suggested remit: To appraise the clinical and cost effectiveness of setmelanotide within its marketing authorisation for treating obesity and hyperphagia caused by Bardet-Biedl Syndrome (BBS).
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 3947

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol

Stakeholders

Companies sponsors Rhythm Pharmaceuticals (Setmelanotide)
Others Department of Health and Social Care
  NHS England
Patient carer groups Bardet-Biedl Syndrome UK
Professional groups British Obesity & Metabolic Surgery Society
  Royal College of Physicians
Comparator companies Novo Nordisk (semaglutide)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Government
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
22 February 2024 - 14 March 2024 Draft guidance: 2
07 December 2023 Committee meeting: 3
14 September 2023 Committee meeting: 2
03 August 2023 - 24 August 2023 Draft guidance
13 July 2023 Committee meeting
15 February 2023 In progress. In progress.
09 November 2022 Invitation to participate
30 March 2022 The topic was discussed at the Topic Selection Oversight Panel (TSOP) in March 2022. The panel concluded that the topic was suitable for a Highly Specialised Technologies (HST) evaluation.
30 March 2022 Topic selection
15 December 2021 (14:00) Scoping workshop
03 November 2021 - 01 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 September 2021 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual